Evaxion A/S (EVAX) Form 3 outlines warrants and share holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Evaxion A/S filed an initial insider ownership report detailing equity interests related to its ordinary shares. The filing lists warrants exercisable into 2,500,000 ordinary shares at an exercise price of $0.12 per share, expiring on December 31, 2031, with vesting at 1/36 per month over 36 months from the initial exercise date.
It also reports 2,286,150 ordinary shares held indirectly, noted as owned "By James Noble," who is identified in a footnote as the spouse of Dr. Tayton-Martin. The entry reflects holdings rather than new buy or sell transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Evaxion A/S
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Warrants — 2,500,000 shares (Direct);
Ordinary Shares — 2,286,150 shares (Indirect, By James Noble)
Footnotes (1)
- Mr. Noble is Dr. Tayton-Martin's spouse. Vesting is 1/36 per month over 36 months from the initial exercise date indicated.
FAQ
What does Evaxion A/S (EVAX) disclose in this Form 3 filing?
The Form 3 shows initial insider holdings in Evaxion A/S. It reports warrants for 2,500,000 ordinary shares at $0.12 per share and 2,286,150 ordinary shares held indirectly, establishing a baseline of reported ownership rather than recording new transactions.
Are there any buy or sell transactions in this Evaxion A/S Form 3?
No new buy or sell transactions are reported. The entries are classified as holdings, with transaction counts indicating unknown or neutral direction. Form 3 primarily establishes the insider’s existing ownership when they become subject to reporting, rather than documenting trades.
What are the key terms of the Evaxion A/S warrant position reported?
The warrants relate to 2,500,000 underlying ordinary shares, with an exercise price of $0.12 and an expiration date of December 31, 2031. Vesting occurs monthly at 1/36 over 36 months, starting from the stated initial exercise date in the filing.